Zepbound® (Tirzepatide) 2.5mg/0.5mL Injection Pen – Once-Weekly Weight Management Therapy

Zepbound® (Tirzepatide) 2.5mg/0.5mL Injection Pen is an advanced once-weekly prescription medication designed to support long-term weight management when combined with a reduced-calorie diet and increased physical activity. The 2.5mg strength is the recommended starting dose, allowing patients to begin treatment gradually while helping minimize gastrointestinal side effects before dose escalation. It is intended for treatment initiation rather than long-term maintenance.

Powered by tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, Zepbound works by targeting the body’s natural metabolic pathways involved in appetite regulation, food intake, and energy balance. This dual-action mechanism helps users feel fuller for longer, reduces hunger, slows stomach emptying, and supports consistent, clinically meaningful weight loss when paired with healthy lifestyle changes.

The Zepbound 2.5mg injection pen is supplied as a convenient, prefilled single-dose pen designed for simple once-weekly subcutaneous administration. Whether injected into the abdomen, thigh, or upper arm, the pen offers an easy-to-use solution for individuals beginning a medically supervised weight management program.

Key Features

• Contains Tirzepatide 2.5mg/0.5mL
• Easy-to-use prefilled injection pen
• Once-weekly subcutaneous administration
• Recommended treatment initiation dose
• Supports appetite control and reduced calorie intake
• Helps promote sustainable weight management when combined with diet and exercise
• No daily dosing required
• Manufactured to pharmaceutical quality standards

How Zepbound Works

Unlike traditional weight management medications that target only one hormone pathway, tirzepatide activates both the GIP and GLP-1 receptors. This dual mechanism helps:

• Increase feelings of fullness after meals
• Reduce appetite and food cravings
• Slow gastric emptying
• Improve metabolic regulation
• Support gradual, consistent body weight reduction

These combined effects can make maintaining a calorie-controlled lifestyle more achievable over time.

Who May Benefit

Under the guidance of a qualified healthcare provider, Zepbound may be prescribed for adults with:

• Obesity
• Overweight with at least one weight-related medical condition
• Individuals beginning a medically supervised weight loss program

Zepbound doses is intended to be used alongside healthy nutrition, increased physical activity, and ongoing medical monitoring. It is also approved in the U.S. for certain adults with obesity and moderate-to-severe obstructive sleep apnea.

Product Specifications

• Brand: Zepbound®
• Active Ingredient: Tirzepatide
• Strength: 2.5mg/0.5mL
• Dosage Form: Prefilled Injection Pen
• Administration: Subcutaneous injection
• Frequency: Once weekly
• Treatment Stage: Initial dose (Weeks 1–4)

Benefits

• Supports clinically guided weight reduction
• Helps reduce hunger throughout the day
• Encourages portion control
• Convenient once-weekly dosing
• User-friendly injection pen
• Designed to fit into long-term weight management programs
• May improve adherence compared with daily medications

Storage

Store refrigerated between 2°C and 8°C (36°F–46°F). Protect from direct light and do not freeze. Follow the manufacturer’s storage instructions before use.

Important Safety Information

Zepbound is a prescription-only medication and should only be used under the supervision of a licensed healthcare professional. It should not be combined with other tirzepatide-containing medicines or GLP-1 receptor agonists unless specifically directed by a healthcare provider. Common side effects may include nausea, vomiting, diarrhea, constipation, decreased appetite, and stomach discomfort. It carries a boxed warning regarding the potential risk of thyroid C-cell tumors observed in animal studies; the relevance to humans is unknown. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).